 |
 |

Crossover Comparison of Timolol and Latanoprost in Chronic Primary Angle-closure Glaucoma
Ramanjit Sihota, MD, FRCS;
Rohit Saxena, MD;
H. C. Agarwal, MD;
Vikas Gulati, MD
Arch Ophthalmol. 2004;122:185-189.
Objective To compare latanoprost and timolol maleate as primary therapy in 60 eyes with chronic primary angle-closure glaucoma after a laser iridotomy.
Methods We performed a prospective, randomized, crossover study of 60 eyes of 30 patients with chronic primary angle-closure glaucoma after laser iridotomy. Patients were randomized to 2 groups: those taking latanoprost once daily or those taking timolol twice daily. Three months after treatment with the first drug, the second drug was substituted. The circadian rhythm of intraocular pressure (IOP) was recorded before the start of therapy, at 3 months, and at 7 months. The fourth month was the washout period for the first drug.
Results The mean baseline IOP was 23.5 ± 2.1 mm Hg, which decreased by 8.2 ± 2.0 mm Hg with latanoprost (P<.001) and by 6.1 ± 1.7 mm Hg with timolol (P = .01). The decrease in IOP was greater for patients taking latanoprost (P<.001). Latanoprost was significantly more effective in eyes having morning and afternoon peaks of IOP. A total of 43 eyes (72%) of patients taking latanoprost and 26 (43%) on timolol achieved a reduction of more than 30% from baseline IOP.
Conclusion There were greater mean and peak IOP reductions achieved with 0.005% latanoprost once daily compared with 0.5% timolol twice daily.
From the Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India. The authors have no relevant financial interest in this article.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma
How et al.
Br J Ophthalmol 2009;93:782-786.
ABSTRACT
| FULL TEXT
Effects of Oxidative Stress in Trabecular Meshwork Cells Are Reduced by Prostaglandin Analogues
Yu et al.
IOVS 2008;49:4872-4880.
ABSTRACT
| FULL TEXT
The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review
Hodge et al.
Br J Ophthalmol 2008;92:7-12.
ABSTRACT
| FULL TEXT
The Effects of Prostaglandin Analogues on Prostanoid EP1, EP2, and EP3 Receptor-Deficient Mice.
Ota et al.
IOVS 2006;47:3395-3399.
ABSTRACT
| FULL TEXT
In Vitro Study of Inflammatory Potential and Toxicity Profile of Latanoprost, Travoprost, and Bimatoprost in Conjunctiva-Derived Epithelial Cells
Guenoun et al.
IOVS 2005;46:2444-2450.
ABSTRACT
| FULL TEXT
|